Clinical efficacy and potential mechanism of the Lianhua Qingwen prescription combined with conventional western medicine in the treatment of mycoplasma pneumoniae pneumonia in children based on Meta-analysis and network pharmacology
Objective:To evaluate the clinical efficacy of the Lianhua Qingwen prescription(连 花 清 瘟 方)combined with conventional Western medicine on mycoplasma pneumoniae pneumonia in children and explore its potential mechanism based on Meta-analysis and network pharmacology.Methods:The randomized controlled trials(RCTs)of conventional Western medicine treatment combined with the Lianhua Qingwen prescription versus conventional treatment on mycoplasma pneumoniae pneumonia from the establishment of each database to March 2022 was retrieved from PubMed,Embase,CNKI,Wanfang database,VIP database and CBM.The Meta-analysis was conducted by RevMan 5.3 system.The included literature was evaluated according to Cochrane system evaluator manual.The chemical components and action targets in the Lianhua Qingwen prescription were screened based on the network pharmacology.Common targets were obtained after taking the intersection with disease targets,and then the key pathways were annotated based on bioinformatics technology to explore the potential mechanism of the Lianhua Qingwen prescription in the treatment of mycoplasma pneumoniae pneumonia.Results:A total of 20 RCTs were included,with a total of 2 031 patients.Meta-analysis showed that total effective rate in the experimental group was significantly higher than the control group.Cough time,fade time of fever,fade time of lung rale were shorter than the control group.The level of CD4+,FEV1,PEF of children after treatment were higher while cytokine IL-6 and CRP were lower than the control group.The safety in the experimental group was higher than the control group.Through network pharmacology methods,234 chemical components and 646 related targets were obtained in the Lianhua Qingwen prescription from online database.There were 80 targets related to the treatment of mycoplasma pneumonia.Quercetin,luteolin,kaempferol,indigo and tryptanthrin may be the main components in the treatment,mainly involving NF-κB signal path,TNF signal path,IL-17 signal path,Toll-like receptor signal path,Th17 cell differentiation and so on.Conclusion:The Lianhua Qingwen prescription can improve the clinical efficacy on mycoplasma pneumoniae pneumonia in children.It has advantages in improving clinical symptoms,enhancing immunity,and improving lung function.Mycoplasma pneumoniae pneumonia can be cured by anti-inflammatory,anti-oxidation,regulating immunity and so on.
The Lianhua Qingwen prescriptionMycoplasma pneumoniaMeta-analysisNetwork pharmacologyPotential mechanism of action
万方数据
维普
